AbbVie/United Therapeutics $350m Voucher Deal: Smart Move?
This article was originally published in Scrip
AbbVie became the latest firm to test the FDA "voucher" strategy as a pathway to success – entering into a $350m deal with United Therapeutics in an effort to get an experimental medicine to the market quicker.
You may also be interested in...
Analysts expect strong uptake for the antisense oligonucleotide (ASO) given the high unmet need in SMA and positive data in multiple studies, while the first ASO approved this year – Sarepta’s Exondys 51 – has seen some pushback from payers despite the lack of DMD therapies.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.